Skip to main content

Advertisement

SpringerLink
Log in

Primary Prevention of HPV through Vaccination: Update on the Current Global Status

  • Management of HPV and Associated Cervical Lesions (L Denny, Section Editor)
  • Published:
Current Obstetrics and Gynecology Reports Aims and scope Submit manuscript

Abstract

Ten years after the first licencing of a prophylactic human papillomavirus (HPV) vaccine, this paper reviews global information on programme coverage, as reported to WHO and from the published and grey literature. As of May 2016, 74 countries report that the HPV vaccine is on the national schedule or reimburse vaccine costs. We also summarise the latest available information on programme implementation, vaccine effectiveness, the nine-valent HPV vaccine and the accumulated safety experience with HPV vaccines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Brotherton JML, Bloem PN. HPV vaccination: current global status. Curr Obstet Gynecol Reports. 2015;4(4):220–33.

    Article  Google Scholar 

  2. Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62. doi:10.4161/hv.29532.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Apter D, Wheeler CM, Paavonen J, Castellsague X, Garland SM, Skinner SR, et al. Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomised, double-blind PATRICIA trial. Clin Vaccin Immunol. 2015;22(4):361–73.

    Article  CAS  Google Scholar 

  4. Nygård M, Saah A, Munk C, Tryggvadottir L, Enerly E, Hortlund M, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol. 2015;22:943–8. doi:10.1128/CVI.00133-15. Study that suggests over 9 years of sustained antibodies are induced by the quadrivalent HPV vaccine.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sankaranarayanan R, Prabhu PR, Pawlita M, Gheit T, Bhatla N, Muwonge R, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. The Lancet Oncology. 2015;17(1):67–77. First cohort study to suggest a protective effect of one dose of quadrivalent HPV vaccine on HPV infection. Further data from this study are awaited to confirm these initial findings.

    Article  PubMed  Google Scholar 

  6. Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls. Clin Infect Dis. 2015;61(5):676–82. doi:10.1093/cid/civ364.

    Article  PubMed  Google Scholar 

  7. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One. 2015;10(7), e0132404. doi:10.1371/journal.pone.0132404. eCollection 2015.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597–603.

    Article  CAS  PubMed  Google Scholar 

  9. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04 adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncol. 2015;16(7):775–86. Analysis suggesting equivalent efficacy to three doses from one or two doses of bivalent HPV vaccine.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Cuschieri K, Kavanagh K, Moore C, Bhatia R, Love J, Pollock KG. Impact of partial bivalent HPV vaccination on vaccine-type infection: a population-based analysis. Br J Cancer advance online publication. 2016. doi:10.1038/bjc.2016.97. First analysis to document population-based impact of one or two doses of bivalent HPV vaccine on HPV infection.

    Google Scholar 

  11. Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR. 2015;64(29):784–92.

    PubMed  Google Scholar 

  12. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics Mar. 2016;137(3):1–9. doi:10.1542/peds.2015-1968.

    Article  Google Scholar 

  13. Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States—2008–2012. Vaccine. 2015;33(13):1608–13. doi:10.1016/j.vaccine.2015.01.084.

    Article  PubMed  Google Scholar 

  14. Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170:445–52. doi:10.1001/jamapediatrics.2015.3926.

    Article  PubMed  Google Scholar 

  15. Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004–2013: correlation with introduction of female and male human papillomavirus vaccination. Sex Transm Dis. 2015;42(12):665–8. doi:10.1097/OLQ.0000000000000369.

    Article  PubMed  Google Scholar 

  16. Smith LM, Strumpf EC, Kaufman JS, Lofters A, Schwandt M, Lévesque LE. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics. 2015;135(5):e1131–40. doi:10.1542/peds.2014-2961.

    Article  PubMed  Google Scholar 

  17. Mesher D, Panwar K, Thomas SL, Beddows S, Soldan K. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 2016;6:e009915. doi:10.1136/bmjopen-2015-009915.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis. 2016;22(1):56–64. doi:10.3201/eid2201.150736.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Mollers M, King AJ, Knol MJ, Scherpenisse M, Meijer CJ, van der Klis FR, et al. Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: results from a longitudinal Dutch cohort study. Vaccine. 2015;33(23):2678–83. doi:10.1016/j.vaccine.2015.04.016.

    Article  CAS  PubMed  Google Scholar 

  20. Arbyn M, Broeck DV, Benoy I, Bogers J, Depuydt C, Praet M, et al. Surveillance of effects of HPV vaccination in Belgium. Cancer Epidemiol. 2016;41:152–8. doi:10.1016/j.canep.2015.12.011.

    Article  PubMed  Google Scholar 

  21. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer. 2016;138:2867–74. doi:10.1002/ijc.30035.

    Article  CAS  PubMed  Google Scholar 

  22. Brotherton JM, Gertig DM, May C, Chappell G, Saville M. HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 2016;204(5):184.

    Article  PubMed  Google Scholar 

  23. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ (Clinical Research Ed). 2012;344:e1401.

    Article  Google Scholar 

  24. Hildesheim A, Gonzalez P, Kreimer AR, Wacholder S, Schussler J, Rodriguez AC, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol. 2016. doi:10.1016/j.ajog.2016.02.021.

    PubMed  Google Scholar 

  25. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Eng J Med. 2015;372(8):711–23. RCT analysis of the nine-valent HPV vaccine showing equivalent immunogenicity as quadrivalent vaccine against types 6/11/16/18 and high efficacy against types 31/33/45/52/58.

    Article  CAS  Google Scholar 

  26. Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136(1):e28–39.

    Article  PubMed  Google Scholar 

  27. Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892–901. doi:10.1016/j.vaccine.2015.06.088.

    Article  PubMed  Google Scholar 

  28. Garland SM, Cheung TH, McNeill S, Petersen LK, Romaguera J, Vazquez-Narvaez J, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12–26 years of age who previously received the quadrivalent HPV vaccine. Vaccine. 2015;33:6855–64.

    Article  CAS  PubMed  Google Scholar 

  29. Macartney KK, Chiu C, Georgousakis M, Brotherton J. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013;36:393–412.

    Article  CAS  PubMed  Google Scholar 

  30. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years. Human Vaccines. 2009;5(10):705–19.

    Article  CAS  PubMed  Google Scholar 

  31. World Health Organization (June 2012). Information sheet. Observed rates of vaccine reactions. Human papilloma virus vaccines. http://www.who.int/vaccine_safety/initiative/tools/HPV_Vaccine_rates_information_sheet.pdf?ua=1. Accessed 10 May 2016.

  32. Brotherton JM, Gold MS, Kemp AS, McIntyre PB, Burgess MA, New South Wales Health HPV Adverse Events Panel, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179(6):525–33.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Kang LW, Crawford N, Tang ML, Buttery J, Royle J, Gold M, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. BMJ. 2008;337:a2642. doi:10.1136/bmj.a2642.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279–84.

    Article  PubMed  Google Scholar 

  35. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112(4):815–20.

    Article  PubMed  Google Scholar 

  36. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95 Suppl 1:S144–50.

    Article  PubMed  Google Scholar 

  37. Global Advisory Committee on Vaccine Safety (GACVS); WHO secretariat. Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS. Expert Rev Vaccines. 2009;8(6):705–16.

    Article  Google Scholar 

  38. Global Advisory Committee on Vaccine Safety, 12–13 June 2007. Wkly Epid Rec 2007; 82: 252–9.

  39. Buttery JP, Madin S, Crawford NW, Elia S, La Vincente S, Hanieh S, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust. 2008;189(5):261–2.

    PubMed  Google Scholar 

  40. Crawford NW, Clothier HJ, Elia S, Lazzaro T, Royle J, Buttery JP. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust. 2011;194(1):16–8.

    PubMed  Google Scholar 

  41. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29(2):95–101.

    Article  Google Scholar 

  42. Global Advisory Committee on Vaccine Safety (GACVS). Report of meeting held 17–18 June 2009. Wkly Epid Rec. 2009;84:325–32.

    Google Scholar 

  43. Sutton I, Lahoria R, Tan I, Clouston P, Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler. 2009;15(1):116–9.

    Article  CAS  PubMed  Google Scholar 

  44. Richards S, Chalkiadis G, Lakshman R, Buttery JP, Crawford NW. Complex regional pain syndrome following immunisation. Arch Dis Child. 2012;97(10):913–5.

    Article  PubMed  Google Scholar 

  45. Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Intern Med. 2014;53(19):2185–200.

    Article  PubMed  Google Scholar 

  46. Brinth LS, Pors K, Theibel AC, Mehlsen J. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine. 2015;33(22):2602–5.

    Article  PubMed  Google Scholar 

  47. Martínez-Lavín M, Martínez-Martínez LA, Reyes-Loyola P. HPV vaccination syndrome. A questionnaire-based study. Clin Rheumatol. 2015;34(11):1981–3.

    Article  PubMed  Google Scholar 

  48. Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a phase III randomized study of healthy women aged 18–45 years. Hum Vaccin. 2011;7(12):1343–58.

    Article  CAS  PubMed  Google Scholar 

  49. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750–7.

    Article  CAS  PubMed  Google Scholar 

  50. Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of Bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccin. 2011;7(Suppl):136–46.

    Article  PubMed  Google Scholar 

  51. National Pharmaceutical Control Bureau, Ministry of Health Malaysia. MADRAC Bulletin April 2011. http://bpfk.moh.gov.my/images/Publications/Newsletter_MADRAC_Bulletin/MADRAC_BULLETIN_APRIL_2011.pdf. Accessed 10 May 2016.

  52. van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13–16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine. 2011;29(28):4601–7.

    Article  PubMed  Google Scholar 

  53. Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J Inorg Biochem. 2011;105(11):1489–99.

    Article  CAS  PubMed  Google Scholar 

  54. Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem. 2011;18(17):2630–7.

    Article  CAS  PubMed  Google Scholar 

  55. Scheller NM, Svanström H, Pasternak B, Arnheim-Dahlström L, Sundström K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54–61. Methodologically strong population-based two-country study including 4 million women demonstrating no increase in risk of multiple sclerosis in women vaccinated against HPV.

    Article  CAS  PubMed  Google Scholar 

  56. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271(2):193–203.

    Article  CAS  PubMed  Google Scholar 

  57. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Agence nationale de sécurité des medicaments et des produits de santé. Vaccins anti-HPV et risque de maladies autoimmunes: étude pharmacoépidémiologique. http://ansm.sante.fr/content/download/80841/1023043/version/1/file/Ansm_Gardasil-Hpv2_Rapport_Septembre-2015.pdf. Accessed 10 May 2016.

  59. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26(11):979–84.

    Article  PubMed  Google Scholar 

  60. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30 Suppl 5:F139–48.

    Article  PubMed  Google Scholar 

  61. WHO/UNICEF Joint reporting Form, 1 May 2016. http://www.who.int/immunization/monitoring_surveillance/data/en/. Accessed 15 May 2016.

  62. WHO V3P. The Vaccine Product, Price and Procurement (V3P) Project. http://www.who.int/immunization/programmes_systems/procurement/v3p/en/. Accessed 19 April 2016.

  63. PAHO/WHO. Eight in 10 adolescent girls in the Americas have access to HPV vaccine, following its introduction in Brazil. Washington DC, March 20, 2014. http://www.paho.org/hq/index.php?option=com_content&view=article&id=9394:el-80-de-las-ninas-adolescentes-de-las-americas-tendra-acceso-a-la-vacuna-contra-el-vph-tras-haberse-introducido-en-brasil-&catid=740:news-press-releases&Itemid=1926&lang=en. Accessed May 2016.

  64. World Health Organization, Department of Immunization, Vaccines and Biologicals. Projections of national annual population 5–74 of age by single year of age and sex, 2010–2020. Geneva; 2016 update. http://www.who.int/immunization/diseases/hpv/UN_population_estimates_9-13_year-old_cohort/en/. Accessed 15 May 2016.

  65. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Weekly Epidemiologic Record WER. 2014;43(89):465–92. Accessed 15 May 2016 http://www.who.int/wer/2014/wer8943.pdf?ua=1 .

  66. BYJU’S, December 28, 2015. http://byjus.com/free-ias-prep/check-cervical-cancer-govt-plans-launch-hpv-vaccine. Accessed 17 May 2016.

  67. Indian Express, 1 March 2016. http://indianexpress.com/article/cities/delhi/delhi-first-state-to-launch-hpv-vaccine-as-public-health-programme-in-schools/ Accessed 17 April 2016.

  68. Graham DM, Isaranuwatchai W, Habbous S, de Oliveira C, Liu G, Siu LL, et al. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer. 2015;121(11):1785–92. doi:10.1002/cncr.29111.

    Article  PubMed  Google Scholar 

  69. Olsen J, Jorgenson TR. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc. 2015;13:4. doi:10.1186/s12962-015-0029-9.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Elfström KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human papillomavirus vaccination of boys and extended catch-up vaccination: effects on the resilience of programs. J Infect Dis. 2016;213(2):199–205. doi:10.1093/infdis/jiv368.

    Article  PubMed  Google Scholar 

  71. Paul K. “Saving lives”: adapting and adopting human papilloma virus (HPV) vaccination in Austria. Soc Sci Med. 2016;153:193e200.

    Article  Google Scholar 

  72. UK Government. JCVI interim position statement on HPV vaccination of men who have sex with men (MSM). 2015. Accessed May 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/373531/JCVI_interim_statement_HPV_vacc.pdf.

    Google Scholar 

  73. Torres-Rueda S, Rulisa S, Burchett H, Mivumbi V, Mounier-Jack S. HPV vaccine introduction in Rwanda: impacts on the broader health system. Sex Reprod Healthc. 2016;7:46–51. doi:10.1016/j.srhc.2015.11.006.

    Article  PubMed  Google Scholar 

  74. Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, et al. Introduction of a national HPV vaccination program into Bhutan. Vaccine. 2015;33(31):3726–30.

    Article  PubMed  Google Scholar 

  75. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571.

    Article  PubMed  Google Scholar 

  76. Baussano I, Lazzarato F, Ronco G, Dillner J, Franceschi S. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries. Int J Cancer. 2013;133(8):1876–81. doi:10.1002/ijc.28197.

    Article  CAS  PubMed  Google Scholar 

  77. Rehn M, Uhnoo I, Kühlmann-Berenzon S, Wallensten A, Sparén P, Netterlid E. Vaccine uptake after school-based delivery—a county-level evaluation of the implementation highest strategies for HPV catch-up vaccination in Sweden. PLoS ONE. 2016;11(3):e0149857. doi:10.1371/journal.

    Article  PubMed  PubMed Central  Google Scholar 

  78. World Health Organization. Scaling-up HPV vaccine introduction. Geneva, 2016 (in press). http://www.who.int/immunization/diseases/hpv/resources/en/index.html.

  79. Herlihy N, Hutubessy R, Jit M. Current global pricing for human papillomavirus vaccines brings the greatest economic benefits to rich countries. Health Aff (Millwood). 2016;35(2):227–34. doi:10.1377/hlthaff.2015.1411.

    Article  Google Scholar 

  80. Pharmaceutical Benefits Scheme. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, solution for injection, 0.5 mL, solution for injection pre-filled syringe single dose, Gardasil®—November 2011. Public Summary document. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-11/pbac-psd-quadrivalent-nov11. Accessed 15 May 2016.

  81. European Centre for Disease Control and Prevention. HPV vaccine schedules in European countries. 2016. http://vaccine-schedule.ecdc.europa.eu/pages/scheduler.aspx. Accessed 15 May 2016.

  82. Patel H, Wilson E, Vizzotti C, Parston G, Prestt J, Darz A. Argentina’s successful implementation of a national human papillomavirus vaccination program. Health Aff (Millwood). 2016;35(2):301–8. doi:10.1377/hlthaff.2015.1416.

    Article  Google Scholar 

  83. Smith MA, Liu B, McIntyre P, Menzies R, Dey A, Canfell K. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 2016;16:52. doi:10.1186/s12879-016-1347-z.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Barbaro B, Brotherton JM. Measuring HPV vaccination coverage in Australia: comparing two alternative population-based denominators. Aust N Z J Public Health. 2015;39(4):326–30. doi:10.1111/1753-6405.12372.

    Article  Google Scholar 

  85. Drolet M, Deeks SL, Kliewer E, Musto G, Lambert P, Brisson M. Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada. Vaccine. 2016;34(16):1874–80. doi:10.1016/j.vaccine.2016.02.069.

    Article  PubMed  Google Scholar 

  86. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. Bull WHO. 2012;90(8):623–8.

    PubMed  PubMed Central  Google Scholar 

  87. PATH, LSTHM. HPV vaccine lessons learned. http://www.rho.org/HPVlessons/. Accessed 17 April 2016. Comprehensive and easily digestible summary (videos, briefs and slides) of a comprehensive review of HPV vaccine delivery experiences across 37 low- and middle-income countries.

  88. Watson-Jones D, Mugo N, Lees S, Mathai M, Vusha S, Ndirangu G, et al. Access and attitudes to HPV vaccination amongst hard-to-reach populations in Kenya. PLoS ONE. 2015;10(6):e0123701. doi:10.1371/journal.pone.0123701.

    Article  PubMed  PubMed Central  Google Scholar 

  89. LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull WHO. 2011;89(11):821–30B.

    PubMed  PubMed Central  Google Scholar 

  90. Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Pub Health. 2012;12:370.

    Article  Google Scholar 

  91. Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2013. BMC Public Health. 2014;14:670.

    Article  PubMed  PubMed Central  Google Scholar 

  92. World Health Organization, Department of Immunization, Vaccines and Biologicals. Haemophilus influenzae type b (Hib). http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/sentinel/Hib/en/. Accessed 15 May 2016.

  93. World Health Organization (2011) Global vaccine action plan. http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/. Accessed 15 May 2016.

  94. Fua LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to increase HPV vaccination acceptance: a systematic review. Vaccine. 2014;32:1901–20.

    Article  Google Scholar 

  95. Niccolai LM, Hansen CE. Practice- and community-based interventions to increase human papillomavirus vaccine coverage a systematic review. JAMA Pediatr. 2015;169(7):686–92.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Baker ML, Figueroa-Downing D, De Oliveira Chiang ED, Villa L, Baggio ML, Eluf-Neto J, et al. Paving pathways: Brazil’s implementation of a national human papillomavirus immunization campaign. Rev Panam Salud Publica. 2015;38(2):163–6.

    PubMed  Google Scholar 

  97. Raesima MM, Forhan SE, Voetsch AC, Hewitt S, Hariri S, Wang SA, et al. Human papillomavirus vaccination coverage among school girls in a demonstration project—Botswana, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(40):1147–9. doi:10.15585/mmwr.mm6440a5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National HPV Vaccination Program Register, School of Population and Global Health, University of Melbourne, PO Box 310, East Melbourne, VIC, 8002, Australia

    Julia M. L. Brotherton

  2. Department of Essential Medicines and Health Products, World Health Organization, Av Appia 20, 1211, Geneva, Switzerland

    Patrick L. F. Zuber

  3. Expanded Programme of Immunization, World Health Organization, Avenue Appia 20, 1211, Geneva, Switzerland

    Paul J. N. Bloem

Authors
  1. Julia M. L. Brotherton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick L. F. Zuber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul J. N. Bloem
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julia M. L. Brotherton.

Ethics declarations

Conflict of Interest

Julia M. L. Brotherton declares to have been an investigator on investigator-designed unrestricted epidemiological research grants partially funded through Seqirus/Merck, but has received no personal financial benefits.

Patrick L.F. Zuber and Paul J. N. Bloem declare no conflict of interest.

The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the World Health Organization.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Management of HPV and Associated Cervical Lesions

Appendix

Appendix

Table 1 Countries with HPV vaccines in their national immunisation programmes, by 31 June 2016
Full size table

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brotherton, J.M.L., Zuber, P.L.F. & Bloem, P.J.N. Primary Prevention of HPV through Vaccination: Update on the Current Global Status. Curr Obstet Gynecol Rep 5, 210–224 (2016). https://doi.org/10.1007/s13669-016-0165-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13669-016-0165-z

Keywords

Search

Navigation